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Abstract
Background and Purpose:	 Irritable	bowel	 syndrome	 (IBS)	 affects	10%‐20%	of	 the	
adult	population	and	is	characterized	by	abdominal	symptoms	without	relevant	or‐
ganic disease. There are numerous clinical trials available investigating the relation‐
ship	between	IBS,	lactose	maldigestion	(LM),	and	lactose	intolerance	(LI),	but	there	
have	been	no	meta‐analyses	on	this	topic	yet.	We	aimed	to	assess	the	prevalence	of	
LM,	objective	and	subjective	(self‐reported)	LI	in	IBS	patients	compared	to	healthy	
controls (HC) without IBS.
Methods:	 A	 systematic	 literature	 search	 was	 conducted	 up	 to	 24	 April	 2018	 in	
PubMed,	Embase,	and	Cochrane	Library.	Adult	IBS	patients	had	to	be	diagnosed	ac‐
cording	 to	 the	 Rome	 criteria	 or	 other	 well‐defined	 criteria	 system.	 We	 enrolled	
controlled studies including healthy adult participants without IBS, as control group. 
Odds	ratios	with	95%	confidence	intervals	were	calculated.
Key Results:	Altogether	14	articles	were	suitable	for	statistical	analyses.	IBS	patients	
reported	themselves	significantly	more	frequently	lactose	intolerant	than	HCs	(odds	
ratio	[OR]	=	3.499;	95%	confidence	interval	[CI]	=	1.622‐7.551).	Generally,	there	was	
no	 significant	 difference	 in	 the	prevalence	of	 LM	based	on	 ingested	 lactose	dose	
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1  | INTRODUC TION
Irritable	bowel	syndrome	 (IBS)	 is	one	of	 the	most	 frequently	diag‐
nosed disorders in gastroenterology, which can be defined by the 
Rome	 IV	 criteria	 system.1‐3	 It	 is	 characterized	 by	 abdominal	 pain	
related to defecation, and associated with a change in stool fre‐
quency	 or	 consistency	 (diarrhea,	 constipation,	 or	 a	 combination	
of these), without any organic disease or pathological abnormality 
of	 the	gut‐wall.4 Four subtypes of IBS can be separated: diarrheal 
(IBS‐D),	constipation	(IBS‐C),	mixed	or	alternating	(IBS‐M/A)	and	un‐
classified	 (IBS‐U)	 form.5,6	 IBS	can	 lead	 to	 significant	quality	of	 life	
impairment, decreased work productivity and an increase of health 
care and social costs.7‐10 The prevalence of IBS is high in Western 
countries,	affecting	10%‐20%	of	the	adult	population.11‐13 Its patho‐
genesis remains unknown, but numerous factors may contribute to 
its development.3,14‐16 Treatment is often multimodal, comprising 
of	 non‐pharmacological	 and	 pharmacological	 methods.	 A	 novel	
effective	 treatment	 option	 is	 a	 low‐FODMAP	 diet	 (Fermentable	
Oligosaccharides, Disaccharides, Monosaccharides, and Polyols), 
which suggests that certain food types, containing disaccharides like 
lactose, can trigger symptoms of patients with IBS.17‐19
Lactose	 intolerance	 (LI)	 is	 a	 condition	 characterized	 by	 clinical	
symptoms	 after	 ingestion	 of	 lactose‐containing	 products,	 caused	
by	 lactose	maldigestion	 (LM).20	 The	most	 common	cause	of	 LM	 is	
primary	(adult‐type)	hypolactasia.3	LI	affects	25%	of	the	Caucasian	
population.	Males	and	females	are	equally	affected.21,22 Because of 
lactase deficiency, lactose can reach the large intestine where it is 
fermented	 by	 colonic	 bacteria.	 Short‐chain	 fatty	 acids,	 gases	 (H2, 
CO2 and CH4) and other products will be produced by the fermenta‐
tion which can cause luminal distension and lead to different gastro‐
intestinal symptoms. The most common complaints are abdominal 
pain and discomfort, bloating, flatulence, and diarrhea, similarly as 
in IBS.20,23‐25 Due to the potential pathogenetic factors of IBS (al‐
tered gastrointestinal motility, changes of gut microbiome, visceral 
hypersensitivity,	anxiety,	etc),	food	intolerances,	such	as	LI,	are	more	
frequent	 in	 this	 disease,	 however,	 the	 prevalence	 of	 LM	does	 not	
differ compared with the healthy population. More IBS patients have 
symptoms at lower lactose doses and their symptoms are more se‐
vere. Moreover, many IBS patients think that their abdominal symp‐
toms are related to lactose intake, even though no objective tests 
of	LM	were	carried	out.26‐30 The available diagnostic methods for 
diagnosing	LM	or	LI	are	based	on	several	approaches,	including	lac‐
tose	breath	test	(LBT),	lactose	tolerance	test	(LTT),	genetic	test	and	
assessment of lactase activity in jejunal biopsy specimens.3 The re‐
striction	of	lactose	intake	or	the	replacement	of	the	lactase	enzyme	
can alleviate these symptoms.3,21
There are numerous clinical trials investigating the connection 
between	IBS,	LM,	and	LI,	but	to	our	best	knowledge	no	meta‐analy‐
ses have been performed up to this day.
Given the uncertain connection between IBS and lactose con‐
sumption‐related	 disorders,	 we	 performed	 a	 systematic	 literature	
search	and	meta‐analysis	in	this	important	topic	with	the	aim	to	as‐
sess	the	prevalence	of	LM,	objective	and	subjective	LI	in	IBS	patients	
compared to healthy controls (HC).
2  | MATERIAL S AND METHODS
Our	 work	 was	 planned	 and	 conducted	 according	 to	 PRISMA	
(Preferred	 Reporting	 Items	 for	 Systematic	 Reviews	 and	 Meta‐
Analyses)	2009	Statement	(Table	S1).
2.1 | Searching strategy
Our systematic literature search was based on the PICO format: 
Participants:	subjects	who	underwent	any	form	of	LM	or	LI	assess‐
ment; Intervention: IBS patients; Comparison: healthy controls; 
(OR	=	1.122;	95%	CI	=	0.929‐1.356)	and	test	type	(OR	=	1.156;	95%	CI	=	0.985‐1.356).	
However,	 significantly	 more	 IBS	 patients	 had	 objective	 LI	 (OR	=	2.521;	 95%	
CI	=	1.280‐4.965).
Conclusions and Inferences:	Lactose	intolerance,	but	not	LM	is	more	frequent	among	
patients	with	IBS	compared	to	HCs.	According	to	our	results,	IBS	among	other	func‐
tional	bowel	disorders	is	a	possible	contributing	factor	of	LI	in	people	with	LM.
K E Y W O R D S
irritable bowel syndrome, lactose intolerance, lactose maldigestion
Key Points
• The connection between IBS and lactose intolerance is 
not clearly described yet, therefore we performed 
meta‐analysis	to	explore	this	association.
• We proved that lactose intolerance is more common in 
IBS,	however,	 the	 frequency	of	 lactose	maldigestion	 is	
almost the same compared to healthy people.
• This suggests that IBS is a possible contributing factor in 
lactose intolerance among lactose maldigesters.
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Outcomes:	 prevalence	 of	 LM,	 subjective/objective	 LI.	 It	 was	 con‐
ducted	 by	 two	 independent	 reviewers	 (JC	 and	 PV)	 to	 find	 all	 rel‐
evant	articles	on	the	prevalence	of	LM,	subjective	and	objective	LI	
in	IBS	compared	to	HCs,	up	to	24	April	2018	(first	search:	20	June	
2017). The search covered three major databases (PubMed, Embase, 
and	 the	 Cochrane	 Library)	 with	 the	 terms	 “(‘irritable	 bowel	 syn‐
drome’	OR	 ‘IBS’)	 AND	 (‘lactose	 intolerance’	OR	 ‘lactose	maldiges‐
tion’	OR	‘lactose	malabsorption’).”	The	reference	lists	of	the	relevant	
articles were hand searched and all appropriate records identified 
were	 included	 in	 the	 screening	process.	After	 this	 search	process,	
language (only English) and species (only humans) filters were used. 
Duplicates	were	removed	with	EndNote	X4	and	manually,	and	then	
title and abstract screening was performed by the two reviewers to 
identify potentially eligible articles. Disagreements were resolved by 
consensus.
2.2 | Eligibility criteria
In	our	meta‐analysis,	we	included	all	studies	investigating	the	con‐
nection	between	IBS,	lactose	consumption‐related	symptoms,	and	
maldigestion in comparison with HC group. Retrospective studies 
were	also	included.	The	length	of	follow‐up	was	not	a	reason	for	
either	 inclusion	or	exclusion.	Only	articles	written	 in	English	and	
those	examining	the	effect	of	lactose	ingestion	in	human	IBS	pa‐
tients were included in this study. Short conference abstracts or 
papers	not	available	in	full‐text	format	were	excluded.	By	defini‐
tion, adult IBS patients (17 years or above) had to be diagnosed 
according to the Rome or, in articles that were not recently 
published,	 according	 to	 any	 other	 well‐defined	 criteria	 system.	
Articles	without	clear	definitions	of	IBS,	or	in	which	small	intesti‐
nal bacterial overgrowth or any other organic diseases (inflamma‐
tory bowel disease, celiac disease, etc) were reported or suspected 
in	the	background,	were	excluded	from	the	analysis.	We	enrolled	
controlled studies which included healthy adult participants (with‐
out organic disease) who did not fulfill IBS criteria, as a control 
group.	Only	 articles	 reporting	 data	 about	 the	 prevalence	 of	 LM	
and/or	subjective/objective	LI	in	IBS	and	HC	group	were	analyzed	
statistically.
2.3 | Quality assessment of the individual studies
The	 quality	 and	 the	 biases	 of	 the	 included	 studies	were	 analyzed	
with	the	Newcastle‐Ottawa	Scale	(NOS)	for	case‐control	studies.31 
Two	 authors	 (IMC,	 PV)	 independently	 assessed	 the	 risk	 of	 bias	 in	
each paper included in the statistical analysis. Disagreements were 
resolved by consensus. If the discussion did not result in consensus, 
a	third	author	was	consulted	(PH).	The	NOS	for	case‐control	studies	
contains eight items covering three main domains (selection, compa‐
rability	and	exposure).	A	study	can	be	awarded	a	maximum	of	one	
star	 for	 each	numbered	 item;	on	 the	 contrary,	 a	maximum	of	 two	
stars	can	be	given	for	comparability.	Each	 item	was	rated	as	 “high	
risk”	 (zero	 stars),	 “low	 risk”	 (one	 star)	 or	 “unclear	 risk”	 (zero	 stars)	
corresponding to the definitions.
2.4 | Data extraction
At	 the	end	of	 the	 screening	process,	 relevant	data	were	 indepen‐
dently	 extracted	 from	 studies	 by	 two	 independent	 reviewers	 (JC	
and	 PV).	 These	 included:	 prevalence	 of	 LM	 and	 LI	 (subjective	 or	
objective) as the outcome parameters, first author, year of publica‐
tion and country of origin, study design, basic characteristics of the 
study	population	(age,	percentage	of	females	and	IBS	subtypes,	size	
of the study groups), diagnostic criteria for IBS, diagnostic methods, 
thresholds and lactose dose used to diagnose maldigestion. Data for 
the	risk	of	bias	(NOS)	assessment	were	collected	as	well.	Extracted	
data	were	validated	by	five	co‐authors	(ZsSz;	DP;	MB;	ÁV;	JT).
2.5 | Outcome measure
The	 prevalence	 of	 LM,	 subjective	 and	 objective	 LI	were	 the	main	
outcome	parameters	in	our	analysis.	LM	can	be	diagnosed	through	
different ways,21	 the	 non‐invasive	 and	 inexpensive	 LBT	 and	 LTT	
being the most common methods. The sensitivity and specificity 
of these tests depends on the lactose dose, but they are relatively 
high	(78%	and	93%).32 Before (baseline) and after the ingestion of a 
given amount of lactose, breath and blood samples are collected at 
different	 time	points	 for	a	period	of	 time	and	end‐alveolar	H2 and 
blood	glucose	concentrations	are	measured.	A	certain	rise	of	H2 (or 
additionally methane) and/or no rise of blood glucose (or additionally 
galactose) above the baseline levels are considered diagnostic for 
lactose maldigestion. The amount of ingested lactose and the diag‐
nostic thresholds were different in the studies. Testing of lactase 
activity in mucosal biopsy samples from duodenum or jejunum is the 
gold	standard	method	in	the	diagnosis	of	LM,	but	due	to	the	inva‐
siveness,	high	costs	and	patchy	expression	of	the	enzyme	it	is	per‐
formed	less	frequently,	compared	to	the	tests	mentioned	above.	The	
availability of genetic testing of the genes associated with lactase 
non‐persistence	 (C/T_13910	 with	 CC	 genotype;	 G/A_22018	 with	
GG genotype) is variable, and its costs are relatively high.21
Participants	 with	 LM	 who	 had	 abdominal	 symptoms	 during	
or shortly after lactose test were defined as objectively lactose 
intolerant. Participants reporting before any tests, that their symp‐
toms	can	be	in	connection	with	ingestion	of	lactose‐containing	prod‐
ucts, were defined as subjectively lactose intolerant.
2.6 | Statistical analysis
Pooled	 odds	 ratios	 (OR)	were	 calculated	with	 95%	 confidence	 in‐
tervals	(CI).	Random	effects	and	fixed	model	were	applied	at	all	of	
analyses	 with	 DerSimonian‐Laird33 estimation. Statistical hetero‐
geneity	was	 analyzed	 using	 the	 I2 and	 the	 chi‐square	 test	 to	 gain	
probability‐values;	P < 0.1 was defined to indicate significant heter‐
ogeneity.34	Subgroups	of	test	type	(LBT,	LTT,	lactase	activity,	and	ge‐
netic	test)	and	lactose	dosages	(10‐18	g,	20‐25	g,	and	40‐50	g)	were	
created in the analysis on the outcomes. Statistical analyses were 
performed	using	the	Comprehensive	Meta‐Analysis	Software	(CMA,	
Biostat,	NJ,	USA).	Forest	plots	were	used	to	present	the	results	of	
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the	meta‐analyses.	To	check	for	publication	bias,	the	visual	inspec‐
tion of funnel plots and Eggers’ tests were performed.
3  | RESULTS
3.1 | Search results
Using the terms mentioned above, we found 647 articles in the 
three databases for evaluation, 213 in PubMed, 413 in Embase and 
21	in	Cochrane	Library.	We	also	examined	14	further	articles	from	
the reference lists of relevant articles, so 661 articles were found 
in	total.	After	using	the	 language	(only	English)	and	species	(only	
humans)	filters	in	Embase,	PubMed	and	the	Cochrane	Library,	520	
of 647 studies were further assessed and none of the articles from 
the	reference	lists	were	excluded.	After	removing	duplicates,	title	
and	abstract	screening,	89	articles	reporting	on	lactose	consump‐
tion‐related	 disorders	 in	 IBS	 and	 eligible	 for	 further	 evaluation	
were	 found.	The	detailed	 screening	of	 the	 full‐text	papers	 iden‐
tified 16 articles for further assessment, of which two were not 
suitable	 for	 statistical	 analysis.	Altogether	14	 case‐control	 stud‐
ies	met	the	inclusion	criteria	and	remained	for	quantitative	analy‐
sis.26,27,35‐46 The flow chart of the systematic literature search was 
based	on	the	PRISMA	2009	guideline	and	is	detailed	on	Figure	1.	
At	the	time	of	the	literature	search,	we	found	no	eligible	paper	that	
used	 the	most	 recent	 diagnostic	 criteria	 (Rome	 IV)	 for	 IBS.	 The	
basic characteristics of the articles and the raw data are summa‐
rized	in	Tables	1	and	S2.	The	proportion	of	each	IBS	subtype	and	
the	used	lactose	doses,	diagnostic	methods	for	LM	and	thresholds	
in	the	studies	included	in	the	meta‐analysis	are	detailed	in	Table	2.	
A	quality	assessment	(NOS)	of	the	articles	is	summarized	in	Tables	
3 and S3.
3.2 | Lactose maldigestion and IBS
In	 13	of	 the	14	 articles,	 LM	was	objectively	 tested	with	 LBT,	 LTT	
or genetic testing. There were not enough controlled studies with 
lactase activity measurement to carry out a correct statistical analy‐
sis.	 In	one	of	 the	 included	 case‐control	 studies,	 only	 subjective	 LI	
was assessed.42
Based on the ingested lactose dose used in the different studies 
three	 subgroups	were	made:	 10‐18	g;	 20‐25	g;	 40‐50	g	 (Figure	 2).	
Overall there was no significant difference in the prevalence of 
LM	between	IBS	and	HC	groups	(OR	=	1.122;	95%	CI:	0.929‐1.356;	
P = 0.232). The I2 test showed no significant heterogeneity 
(I2 = 0.000%; P	=	0.479).	We	did	not	find	significant	difference	either	
between (P	=	0.121),	or	within	the	subgroups:	(1)	OR	=	1.420,	95%	CI:	
0.873‐2.309,	P = 0.158 (I2 = 0.000%; P	=	0.810);	(2)	OR	=	0.926,	95%	
CI:	0.711‐1.206,	P = 0.568 (I2 = 11.037%; P = 0.338); (3) OR = 1.356, 
95%	CI:	0.977‐1.882,	P = 0.068 (I2 = 0.000%; P = 0.651). There was 
no significant heterogeneity within the subgroups.
F I G U R E  1  PRISMA‐flowchart	of	the	
systematic literature search. IBS: irritable 
bowel syndrome; SIBO: small intestinal 
bacterial overgrowth
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TA B L E  2  The	percentage	of	IBS	subtypes	and	the	diagnostic	methods	and	thresholds	used	in	the	analyzed	studies
First author, year, 
reference number
IBS subtypes 
(%)
Diagnostic 
method for LM
Amount of lactose 
(g) Diagnostic threshold for LM
Bianchi Porro et 
al.	(1983)35
No	data LBT,	LTT,	lactase	
activity (jejunal 
biopsy)
LBT:	50 
LTT:	100
LBT:	>20	ppm	H2 rise 
LTT:	<20	mg/100	mL	rise	of	blood	glucose 
lactase	activity:	≤39	IU/g	protein
Gwee et al. 
(1996)36
IBS‐D:	86 
IBS‐C:	9 
IBS‐M/A:	5
LBT 50 No	data
Vesa	et	al.	
(1998)37
No	data LTT 50 Blood	glucose	elevation	<1.1	mmol/L	(20	mg/100	mL)	and	
maximal	rise	in	blood	galactose	concentration	
≤0.3	mmol/L	(5	mg/100	mL)
Goldstein et al. 
(2000)38
No	data LBT 18 ≥20	ppm	rise	of	H2 or	≥5	ppm	rise	of	CH4 over baseline 
value
Vernia	et	al.	
(2001)27
IBS‐D:	24.8 
IBS‐C:	13.3 
IBS‐M/A:	17.1
LBT 0.5 g/kg body 
weight up to a 
maximum	of	25	g
H2	peak	exceeding	20	ppm	over	the	baseline	values
Parry et al. 
(2002)39
No	data LBT,	LTT 50 A	failure	of	plasma	glucose	to	rise	by	more	than	1.1	mmol/L	
from	baseline.	A	rise	in	the	breath	hydrogen	value	above	
20 ppm from baseline
Lanng	et	al.	
(2003)40
No	data LTT 50 Glucose	level	rise	≤1.3	mmol/L
Farup et al. 
(2004)41
No	data LBT 25 Peak values 
of H2	breath	excretion	>20	ppm	above	the	lowest	
preceding value, peak CH4	excretion	>12	ppm	above	
baseline, and/or combined H2 and CH4	increase	>15	ppm	
were considered 
diagnostic
Saberi‐Firoozi	et	
al. (2007)42
No	data ‐ ‐ ‐
Corlew‐Roath	et	
al.	(2009)43
No	data LBT 50 H2, CH4, and CO2 were tested (threshold: no data)
Yakoob et al. 
(2011)44
IBS‐D:	100 LBT 50 H2 rise above baseline of 20 ppm
Kumar	et	al.	
(2012)45
IBS‐D:	52 
IBS‐C:	35 
IBS‐M/A:	13
Genetic test ‐ C/T_13910	(CC	genotype)/G/A_22018	genetic	variant	(GG	
genotype)
Yang et al. 
(2013)26
IBS‐D:	100 LBT,	genetic	test 10, 20, 40 ≥20	ppm	H2 rise	above	the	baseline,	C/T_13910	(CC	
genotype)
Xiong	et	al.	
(2014)46
IBS‐D:	100 LBT 25 Peak	hydrogen	breath	excretion	of	20	ppm	above	the	
baseline level
IBS‐D/C/M/A,	 irritable	bowel	syndrome‐diarrheal/constipation/mixed/alternating	subtype;	LBT,	 lactose	breath	test;	LM:	 lactose	maldigestion;	LTT,	
lactose tolerance test.
According	to	the	test	methods,	three	subgroups	were	made:	(1)	
genetic	test;	(2)	LBT	and	(3)	LTT	(Figure	3).	Overall,	there	was	no	sig‐
nificant	difference	in	the	prevalence	of	LM	between	IBS	patients	and	
HCs	(OR	=	1.156;	95%	CI:	0.985‐1.356;	P	=	0.077)	and	the	analyzed	
studies were homogeneous (I2 = 0.548%; P	=	0.590).	We	did	not	find	
significant difference either between (P = 0.548) or within the sub‐
groups:	(1)	OR	=	1.243,	95%	CI:	0.922‐1.677,	P = 0.154 (I2 = 0.000%; 
P	=	0.664);	 (2)	 OR	=	1.159,	 95%	 CI:	 0.948‐1.416,	 P = 0.150 
(I2	=	4.977%;	 P	=	0.396);	 (3)	 OR	=	0.868,	 95%	 CI:	 0.492‐1.533,	
P = 0.626 (I2 = 0.000%; P = 0.561). There was no significant hetero‐
geneity within the subgroups.
Based on the test type and ingested amount of lactose, four 
subgroups	were	made:	(1)	20‐25	g	LBT;	(2)	40‐50	g	LBT;	(3)	40‐50	g	
LTT	and	(4)	10‐18	g	LBT	(Figure	4).	Overall	there	was	no	significant	
difference	between	IBS	and	control	groups	in	the	prevalence	of	LM	
(OR	=	1.122;	95%	CI:	0.929‐1.356;	P	=	0.232)	and	the	analyzed	studies	
were homogeneous (I2 = 0.000%; P	=	0.479).	LM	was	more	frequent	
among	 IBS	 patients	who	 underwent	 LBT	with	 40‐50	g	 lactose	 (b)	
compared	 to	 HCs	 (OR	=	1.692;	 95%	 CI:	 1.134‐2.527;	 P = 0.010; 
I2 = 0.000%; P	=	0.938).	 Between	 (P = 0.051) and within the other 
subgroups	there	was	no	significant	difference:	(1)	OR	=	0.926,	95%	
CI:	0.711‐1.206,	P = 0.568 (I2 = 11.037%; P = 0.338); (c) OR = 0.868, 
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95%	 CI:	 0.492‐1.533,	 P = 0.626 (I2 = 0.000%; P = 0.561); (4) 
OR	=	1.420,	95%	CI:	0.873‐2.309,	P = 0.158 (I2 = 0.000%; P	=	0.479).	
There was no significant heterogeneity within the subgroups.
3.3 | Lactose intolerance
Only	four	case‐control	studies	published	data	about	self‐reported	(sub‐
jective)	LI.26,37,41,42	Our	results	(Figure	5)	showed	that	subjective	LI	was	
more common in IBS compared to HCs, patients reported more often 
that	 their	 abdominal	 symptoms	 can	 be	 related	 to	 lactose‐containing	
products	(OR	=	3.499;	95%	CI:	1.622‐7.551;	P	=	0.001).	The	examined	
population was significantly heterogeneous (I2 = 86.774%; P = 0.000).
There	 were	 three	 articles	 available	 reporting	 on	 objective	 LI	
(Figure 6).26,27,46 Significantly more maldigester IBS patients re‐
ported abdominal symptoms during or shortly after the diagnos‐
tic	 test	 compared	 to	 controls	 (OR	=	2.521;	 95%	 CI:	 1.280‐4.965;	
P = 0.008), but our result is limited by the heterogeneity of the ana‐
lyzed	population	(I2 = 74.866%; P = 0.003).
TA B L E  3  The	quality	and	risk	of	bias	assessment	of	the	included	studies	according	to	Newcastle‐Ottawa	Scale	for	case‐control	studies31
First author, year, reference 
number
Selection Comparability Exposure NOS 
summarized 
scoreItem 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8
Bianchi	Porro	et	al.	(1983)35 0 * * * ** * * 0 7/9
Gwee	et	al.	(1996)36 0 * 0 0 * * * 0 4/9
Vesa	et	al.	(1998)37 * 0 * * * * * 0 6/9
Goldstein et al. (2000)38 * * 0 0 ** * * 0 6/9
Vernia	et	al.	(2001)27 * * * * 0 * * 0 6/9
Parry et al. (2002)39 * * 0 * * * * 0 6/9
Lanng	et	al.	(2003)40 * * * * ** * * 0 8/9
Farup et al. (2004)41 * * * * ** * * 0 8/9
Saberi‐Firoozi	et	al.	(2007)42 * * * 0 0 * 0 0 4/9
Corlew‐Roath	et	al.	(2009)43 * * 0 0 0 * * 0 4/9
Yakoob et al. (2011)44 * * 0 * ** * * * 8/9
Kumar	et	al.	(2012)45 * * 0 0 ** * * 0 6/9
Yang et al. (2013)26 * * 0 * ** * * 0 7/9
Xiong	et	al.	(2017)46 * * * * ** * * * 9/9
The	NOS	consists	of	eight	numbered	items,	divided	into	three	main	sections	(selection,	comparability,	and	exposure).	Each	numbered	item	can	be	re‐
warded	with	maximum	one	star;	comparability	can	be	awarded	with	two	stars.	The	studies	with	maximum	of	nine	stars	representing	the	highest‐quality	
trials with the lowest risk of bias. The detailed analysis of each study is represented in Table S3.
NOS,	Newcastle‐Ottawa	Scale.
F I G U R E  2  The	difference	of	LM	between	IBS	and	HCs,	based	on	the	ingested	lactose	dose	(10‐18	g,	20‐25	g,	40‐50	g).	There	was	no	
significant	difference	either	overall,	or	in	the	subgroups.	HC,	healthy	controls;	IBS,	irritable	bowel	syndrome;	LM,	lactose	maldigestion
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F I G U R E  4  The	difference	of	LM	between	IBS	and	HCs,	based	on	the	lactose	dose	and	diagnostic	method.	LM	was	significantly	more	
frequent	in	IBS	only	at	the	LBT	with	the	highest	lactose	dose	(40‐50	g).	HC,	healthy	controls;	IBS,	irritable	bowel	syndrome;	LBT,	lactose	
breath	test;	LM,	lactose	maldigestion
F I G U R E  5  The	difference	of	subjective	(self‐reported)	LI	between	IBS	and	HCs.	Subjective	LI	was	significantly	(P	=	0.001)	more	frequent	
in	IBS	compared	to	the	control	group.	HC,	healthy	controls;	IBS,	irritable	bowel	syndrome;	LI,	lactose	intolerance
F I G U R E  3  The	difference	of	LM	between	IBS	and	HCs,	based	on	the	diagnostic	method	(LBT,	LTT,	genetic	test).	There	was	no	significant	
difference	either	overall,	or	in	the	subgroups.	HC,	healthy	controls;	IBS,	irritable	bowel	syndrome;	LBT,	lactose	breath	test;	LM,	lactose	
maldigestion;	LTT,	lactose	tolerance	test
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4  | DISCUSSION
A	growing	number	of	studies	have	shown	that	intolerance	to	lactose‐
containing	products	and	other	food	types	is	more	frequent	among	
patients with IBS than among healthy subjects, but to our best 
knowledge,	no	meta‐analysis	 investigated	the	association	between	
these two conditions so far. Only two recent reviews by Borghini and 
Bayless et al.3,47	discuss	the	correlation	between	IBS	and	LI.
We	carried	out	 a	 systematic	 literature	 search	 and	quantitative	
data	(meta‐)	analysis	on	the	topic.	A	pooled	analysis	of	14	case‐con‐
trol trials confirmed a significantly higher prevalence of subjective 
and	objective	LI,	whereas	nearly	the	same	prevalence	of	LM	in	IBS	pa‐
tients compared to healthy participants. The underlying mechanism 
remains unknown, but common etiological factors like psychological 
(eg	anxiety)	and	gastrointestinal	dysfunctions	(eg	visceral	hypersen‐
sitivity and altered gut transit) might play a role.28‐30 The visceral hy‐
persensitivity can also be in connection with altered gut microbiome. 
Gut microbiota of IBS patients is generally reduced and has lower 
diversity, compared to healthy controls.48 It has been shown that po‐
tentially pathogenic bacteria (eg Clostridium spp, Ruminococcus spp, 
Streptococcus spp, Enterobacteriaceae members) are more concen‐
trated in IBS patients than in controls.49‐52	A	recent	MRI	(magnetic	
resonance imaging) study concluded that visceral hypersensitivity, 
rather	than	excessive	gas	production	is	responsible	for	carbohydrate	
associated symptoms in patients with IBS.53 The hypersensitivity to 
colonic distension can be transferred to mice by fecal transplanta‐
tion which highlights the role of microbiome.54 Moreover, gut micro‐
biota produces many neuroactive or neuromodulatory metabolites 
(histamine,	 serotonine,	 gamma‐aminobutyric	 acid,	 brain	 derived	
neurotrophic factor, etc), which can potentially lead to peripheral or 
central	neural	sensitization.55,56
Most	studies	have	shown	a	beneficial	effect	of	 lactose‐free	or	
restricted diet in IBS.25,57,58 One reason might be that lactose be‐
longs	to	FODMAPs,	which	are	poorly	absorbed	carbohydrates	lead‐
ing to increased water content in the bowel based on the compounds’ 
osmotic effect and increased gas production by colonic bacterial 
flora, inducing symptoms in patients with IBS and numerous patients 
with functional gastrointestinal disorders. Based on these findings, a 
low‐FODMAP	diet	could	be	beneficial	in	these	patients.17‐19
In	the	present	study,	the	pooled	sample	size	was	large	concerning	
the	key	question	and	the	random	effects	and	fixed	model	were	used	
with	the	DerSimonian	and	Laird	method33 for analysis. Study data 
reflected	no	publication	bias	according	to	the	analyses	of	LM	status	
(Figures S1, S2 and S3), but showed significant bias (small study ef‐
fect) based on heterogeneity in forest plots of subjective and objec‐
tive	LI	(Figures	S4	and	S5).
We	evaluated	 the	quality	 of	 the	 studies	 included	 in	 the	meta‐
analysis	 with	 the	 NOS	 for	 case‐control	 studies,	 which	 showed	
satisfactory scores of the trials with low or medium risk of bias 
(Tables 3 and S3).
The	 strength	 of	 our	 study	 is	 that	 standardized,	 well‐defined,	
rigorous outcome measures were used to assess the role of lactose 
consumption‐related	disorders	in	IBS	patients,	and	a	sufficient	num‐
ber of articles were found to carry out a detailed statistical anal‐
ysis.	Only	 full‐text	 papers	were	 enrolled,	where	 IBS	 patients	with	
appropriate	control	groups	were	present.	According	to	our	results,	
more IBS patients reported themselves lactose intolerant before 
any objective tests compared to HCs, which can be highlighted with 
objective measures: significantly more maldigester IBS patients re‐
ported abdominal symptoms during or shortly after the diagnostic 
test	(objective	LI).	However,	except	for	the	LBT	with	the	highest	lac‐
tose	doses	(40‐50	g),	the	prevalence	of	LM	was	similar	in	the	study	
groups.	Our	meta‐analysis	 is	 the	 first	 to	 provide	 evidence	 for	 the	
connection	between	IBS	and	LI	and	our	former18 data suggest that 
a	lactose‐free	or	lactose‐restricted	diet	(low‐FODMAP)	in	the	treat‐
ment of IBS could improve the therapeutic effect on IBS symptoms 
and	might	decrease	health	care‐related	and	societal	costs.
There are some limitations of our study. Firstly, we focused on 
the	 prevalence	 of	 LM	 and	 subjective/objective	 LI,	 and	 due	 to	 the	
lack of detailed, uniform, controlled, published data, we could not 
F I G U R E  6  The	difference	of	objective	LI	between	IBS	and	HCs.	Objective	LI	was	significantly	(P	=	0.008)	more	frequent	in	IBS	compared	
to	the	control	group.	HC,	healthy	controls;	IBS,	irritable	bowel	syndrome;	LI,	lactose	intolerance
10 of 12  |     VARJÚ et Al.
perform	a	statistical	analysis	of	individual	symptoms.	A	uniform,	con‐
sensus‐based,	well‐comparable	measurement	of	symptom	severity,	
for	example	visual	analog	scale	(VAS)	is	suggested	for	use	in	future	
studies.	 Because	 of	 the	 same	 reasons,	 we	 could	 not	 analyze	 the	
role	of	lactose‐restricted	diet	or	lactase	replacement	in	this	patient	
group;	therefore,	a	network	meta‐analysis	could	be	a	useful	future	
perspective to establish which treatment is better in IBS. Secondly, 
because of the lack of data in the different IBS subtypes, it is not 
clear	which	subgroup	is	mostly	affected	by	LI.	Moreover,	the	diag‐
nostic	criteria	for	IBS	and	the	diagnostic	thresholds	of	LBT	and	LTT	
were different in some studies which could influence the results. The 
sensitivity	and	specificity	of	these	non‐invasive	tests	are	relatively	
high; however, false positive or negative results could have an effect 
on our findings. It should be taken into account that similar activity 
of	lactase	in	two	persons	might	result	in	different	LBT	results	due	to	
the different activity and composition of the intestinal microbiota 
and	the	lactase	non‐persistence	allele	is	not	always	associated	with	
LM.21	Another	difficulty	is	that	it	is	hard	to	identify	the	food,	respon‐
sible	for	the	symptoms.	The	correlation	between	self‐reported	and	
objective	LI	 increases	with	the	ingested	lactose	dose.26 Finally, we 
found significant heterogeneity in the analysis of the subjective and 
objective	LI.	We	could	not	perform	subgroup	analysis	with	different	
amount	of	lactose	in	LI,	however,	it	can	influence	the	frequency	and	
severity of the abdominal symptoms and therefore the prevalence of 
objective	LI,	as	presented	by	Yang	et	al.26
More	 trials	with	 standardized	parameters	 are	necessary	 in	 the	
future	to	provide	the	best	quality	of	evidence	regarding	the	correla‐
tion	between	IBS	and	LI.	Only	patients	fulfilling	the	most	recent	di‐
agnostic	criteria	for	IBS	(Rome	IV)	should	be	included	in	such	studies.	
Outcomes should be reported for each IBS subtypes. Uniform out‐
come	 measures	 (eg	 VAS)	 regarding	 abdominal	 symptoms	 should	
be used to make the different studies scientifically comparable. 
More	randomized	controlled	trials	are	needed	to	provide	evidence	
about	the	role	of	lactose‐free	or	restricted	diet	in	IBS	compared	to	
placebo or lactase replacement. In these studies, a more accurate 
IBS‐Symptom	Severity	Score	 (IBS‐SSS)	 should	be	used	 in	each	 IBS	
subtype, which measures not only the severity of the main symp‐
toms,	but	also	the	quality	of	life.	Clinical	trials	with	different	lactose	
doses	are	also	suggested	to	test	the	role	of	IBS	in	LI	among	lactose	
maldigesters. Yao et al.59 discuss the crucial points and difficulties 
of designing clinical trials in dietary interventions in patients with 
functional gastrointestinal disorders.
5  | CONCLUSION
This	meta‐analysis	is	the	first	to	confirm	that	subjective	and	objec‐
tive	LI	are	more	common	 in	 IBS	patients	compared	 to	 the	healthy	
population,	but	LM	has	the	same	prevalence.	Based	on	these	findings	
and	 literature	 data,	 IBS	 can	 be	 a	 contributing	 factor	 of	 LI	 among	
people	with	LM.	Further	studies	are	needed	to	determine	whether	
a confirmed diagnosis of IBS is an etiological factor in determining 
whether	LM	patients	present	with	LI.
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